

SUPPLEMENTARY FILE

Table S1: Characteristics of study population (secondary objective)

| Population (n=25) | |
|---------------------------------------|--------------------------|
| Gender, female | 22 (88.0%) |
| hTLV (at Off-0), in ml/m [‡] | 3159.5 (2219.4 – 3932.9) |
| Mild (<1600 ml/m), n (%) | 4 (16) |
| Moderate (1600-3200 ml/m), n (%) | 9 (36) |
| Severe (>3200 ml/m), n (%) | 12 (48) |
| Treatment center | |
| Nijmegen | 19 (76.0%) |
| Leuven | 6 (24.0%) |
| Diagnose | |
| ADPKD | 18 (72.0%) |
| ADPLD | 7 (28.0) |

Values are shown as mean \pm SD (standard deviation) for normally distributed data, median (IQR) for non-normally distributed data or in numbers and percentage (%).

[‡]Classification mild/moderate/severe based on Kim (28)

Abbreviations: BOT1, begin of treatment trial 1; hTLV, height adjusted total liver volume; ADPKD, autosomal dominant polycystic kidney disease, ADPLD, autosomal dominant polycystic liver disease

Table S2: Specification of treatment in On-1 and On-2

| # | On-1 | On-2 |
|----|-------------------------------------|------------------|
| 1 | Lanreotide 120mg | Octreotide 40mg |
| 2 | Lanreotide 120mg | Octreotide 40mg |
| 3 | Lanreotide 120mg | Octreotide 40mg |
| 4 | Lanreotide 120mg | Octreotide 40mg |
| 5 | Lanreotide 120mg | Octreotide 40mg |
| 6 | Lanreotide 120mg | Octreotide 40mg |
| 7 | Octreotide 40mg | Lanreotide 120mg |
| 8 | Lanreotide 120mg | Octreotide 40mg |
| 9 | Lanreotide 120mg | Lanreotide 120mg |
| 10 | Lanreotide 120mg | Octreotide 40mg |
| 11 | Lanreotide 120mg | Octreotide 40mg |
| 12 | Lanreotide 120mg | Octreotide 40mg |
| 13 | Lanreotide 120mg | Octreotide 40mg |
| 14 | Octreotide 40mg | Lanreotide 120mg |
| 15 | Lanreotide 120mg | Octreotide 40mg |
| 16 | Octreotide 40mg | Lanreotide 120mg |
| 17 | Octreotide 40mg Lanreotide 120mg | Octreotide 40mg |
| 18 | Lanreotide 120mg | Lanreotide 120mg |
| 19 | Lanreotide 120mg | Lanreotide 120mg |
| 20 | Lanreotide 120mg | Octreotide 40mg |
| 21 | Octreotide 40mg | Lanreotide 120mg |
| 22 | Lanreotide 120mg | Octreotide 40mg |
| 23 | Octreotide 100ug 3dd sc | Lanreotide 120mg |
| 24 | Lanreotide 120mg | Octreotide 40mg |
| 25 | Octreotide 40mg | Lanreotide 120mg |

| | | |
|-----------|-------------------------------------|-------------------------------------|
| 26 | Lanreotide 120mg | Lanreotide 120mg |
| 27 | Octreotide 40mg | Lanreotide 120mg |
| 28 | Lanreotide 120mg | Octreotide 40mg |
| 29 | Lanreotide 120mg | Lanreotide 90mg Lanreotide 120mg |
| 30 | Lanreotide 90mg Lanreotide 120mg | Lanreotide 120mg |
| 31 | Lanreotide 120mg | Lanreotide 90mg Lanreotide 120mg |
| 32 | Lanreotide 120mg | Lanreotide 90mg |
| 33 | Lanreotide 120mg | Lanreotide 90mg Lanreotide 120mg |
| 34 | Lanreotide 120mg | Lanreotide 90mg |

Table S3: Primary and secondary analyses stratified for disease severity.

| Primary objective | Mild and moderate | Severe | P-value |
|--|--------------------------|--------------------|----------------|
| n | 18 | 16 | |
| Gender, female (%) | 17 (94.4) | 13 (81.3) | 0.257 |
| Age at BOT1 (years) | 47.5 (41.8 – 52.5) | 44.0 (41.3 – 49.3) | 0.342 |
| Diagnosis ADPLD / ADPKD (n) | 9 / 9 | 4 / 12 | 0.126 |
| Baseline hTLV (ml/m) On-1 | 2166 (1607 – 2761) | 4279 (3588 – 5813) | <0.001 |
| Baseline hTLV (ml/m) On-2 | 2375 (1631 – 2776) | 5296 (4024 – 5885) | <0.001 |
| Duration (months) On-1 | 11.3 (11.0 – 12.2) | 11.1 (11.0 – 11.7) | 0.403 |
| Duration (months) On-2 | 11.5 (7.7 – 16.7) | 11.4 (5.8 – 12.2) | 0.679 |
| Percent change per 6 months On-1 | -2.7 (-3.8 – 0.2) | -1.6 (-4.1 – 1.2) | 0.558 |
| Percent change per 6 months On-2 | -1.7 (-2.9 – 1.1) | -1.4 (-3.9 – 1.0) | 0.809 |
| Absolute change (ml) – hTLV On-1 | -75 (-162 – 4) | -129 (-332 – 75) | 0.836 |
| Absolute change (ml) – hTLV On-2 | -62 (-105 – 49) | -133 (-328 – 81) | 0.241 |
| Secondary objective | Mild and moderate | Severe | P-value |
| n | 13 | 12 | |
| Baseline hTLV (ml/m) Off-0 | 2572 (1503 – 2888) | 3933 (3365 – 4846) | <0.001 |
| Baseline hTLV (ml/m) Off-1 | 2291 (1438 – 2685) | 3914 (3254 – 5456) | <0.001 |
| Duration (months) Off-0 | 5.7 (5.5 – 6.0) | 6.8 (5.5 – 25.2) | 0.205 |
| Duration (months) Off-1 | 20.2 (15.3 – 26.4) | 16.3 (6.1 – 23.0) | 0.347 |
| Percent change per 6 months Off-0 | 1.0 (-0.2 – 3.3) | 1.8 (0.9 – 4.9) | 0.384 |
| Percent change per 6 months Off-1 | 2.8 (0.7 – 4.1) | 6.2 (4.7 – 7.1) | 0.007 |
| Absolute change (ml) – hTLV Off-0 | 20 (-5 – 72) | 122 (48 – 332) | 0.016 |
| Absolute change (ml) – hTLV Off-1 | 185 (43 – 322) | 406 (187 – 1254) | 0.019 |
| Combined: On-1, Off-1 and On2 | Mild and moderate | Severe | |
| n | 18 | 16 | |
| Duration of total observation period ¹ (months) | 43.5 (40.3 – 48.6) | 43.9 (27.7 – 48.3) | 0.448 |
| Percentage change per 6 months BOT-1 vs EOT-2 (%) | 0.2 (-0.9 – 1.7) | 1.3 (-0.7 – 3.2) | 0.202 |
| Percentage change BOT-1 vs EOT-2 (%) | 1.4 (-6.7 – 12.6) | 5.4 (-5.9 – 23.4) | 0.317 |
| Absolute change BOT-1 vs ETO-2 (ml) | 32 (-97 – 228) | 344 (-284 – 918) | 0.202 |
| Percentage of time treated in total observation period (%) | 53.2 (47.6 – 61.8) | 56.5 (46.6 – 78.3) | 0.388 |

Values are shown median (IQR) for non-normally distributed data.

Classification: mild and moderate, hTLV ≤3200 ml/m; severe, hTLV >3200 ml/m based on Kim (28)